Silk Road Medical Q1 2024 GAAP EPS $(0.36) Beats $(0.40) Estimate, Sales $48.484M Beat $44.676M Estimate
Portfolio Pulse from Benzinga Newsdesk
Silk Road Medical reported Q1 2024 earnings with a smaller loss per share of $(0.36) compared to estimates of $(0.40) and a 16.28% improvement from last year. Sales reached $48.484M, surpassing estimates of $44.676M and marking a 20.81% increase from the previous year.
April 30, 2024 | 8:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Silk Road Medical's Q1 2024 earnings outperformed expectations with a smaller loss and higher sales than anticipated, indicating strong performance and growth.
Beating both EPS and sales estimates typically leads to positive investor sentiment and can result in a short-term stock price increase. The significant improvement over the previous year's performance further strengthens the case for a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100